blog

At the ECCO & ESMO meeting in Stockholm, George Demetri, Section Head in Oncology, talked about his hopes and expectations for his field of sarcoma research

putting a finer point on the pencil

According to George, the most important aspect of the Stockholm meeting was going to be a discussion of prognostic and predictive factors resulting from a Phase III clinical trial, reported earlier in the year at the American Society of Clinical Oncology in Chicago, of the multikinase inhibitor known as Pazopanib. Soft-tissue sarcomas are very heterogeneous and which kinase target is most important is unknown. George says it’s important to determine who would benefit most from this molecularly targetted therapy.

He also mentions a study by Peter Reichardt; a Phase III adjuvant study of imatinib after surgery for GIST (gastrointestinal stromal tumours).

See more videos from ECCO on our YouTube playlist.